BOSTON--(BUSINESS WIRE)--Anagenex, a pioneering drug discovery company pairing large-scale data generation with proprietary artificial intelligence (AI) to discover the next generation of small molecule medicines, today announced the appointment of Adrian Schreyer, Ph.D., as Chief Technology Officer.
“I am thrilled to welcome Adrian to Anagenex. His groundbreaking AI enabled drug discovery experience will drive our platform capabilities to new heights as we work to further enhance our integrated AI and lab capabilities,” said Nicolas Tilmans, CEO of Anagenex. “We look forward to seeing what Adrian will build, armed with our multi billion compound small molecule datasets and ability to build 100 million compound target focused libraries.”
“Anagenex’s unique ability to build molecules at speed and multi-modal selection strategies create the kind of high quality data essential to drive AI and identify molecules to solve challenging biology,” said Adrian Schreyer, Ph.D., CTO of Anagenex. “I am excited to join this team of experienced scientists and engineers to continue the platform’s development and unlock its full potential to find medicines faster.”
Adrian Schreyer is a pioneering leader in AI powered drug discovery with extensive experience in drug development. Prior to joining Anagenex, he spent over a decade at Exscientia where he was a founding member of the team and went on to support the company through a successful IPO while building its AI team from scratch and eventually serving as the company’s Chief Technology Officer. The AI enabled drug discovery engine he designed during his time at Exscientia is one of the only AI platforms to drive compounds from discovery into the clinic. Adrian holds a B.Sc. in Applied Biology from the Bonn-Rhein-Sieg University of Applied Sciences and a Ph.D. in Structural Bioinformatics and Drug Discovery from the University of Cambridge.
Adrian joins the team following the company’s recent announcement of a multi-target collaboration with Nimbus Therapeutics to discover small molecule drugs for multiple challenging targets, underscoring Anagenex’s continued momentum.
About Anagenex
Anagenex is pairing large-scale data generation with AI to discover the next generation of small molecule medicines. Driven by over 300 billion proprietary measurements, Anagenex's precision small molecule discovery platform leverages AI to design and custom chemistry to synthesize 100M target-specific for testing in two weeks, creating a virtuous cycle between real lab experiments and computational tools. Led by a team of highly experienced scientists and engineers, the company’s pipeline is focused on synthetic lethal oncology. Learn more about us at www.anagenex.com or connect with us on LinkedIn.
